Investing
Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics

Published:
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday. The fund bought over 530,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE), as the price of this ETF was down over 2% on the day. Note that this fund is up significantly in the past year.
Specifically, ARK Innovation ETF (NYSEARCA: ARKK) bought 535,305 shares of Fate Therapeutics. At Wednesday’s closing price, this would have valued this purchase at roughly $46.2 million. Even though this is a small fraction of the total holdings, every little bit counts. The fund is up 60% in the past year.
Here’s a look at the other purchases across the ARK ETFs:
Fund | Ticker | Company | Shares |
---|---|---|---|
ARKF | PATH | UiPath | 279,284 |
ARKG | SGFY | Signify Health | 53,916 |
ARKG | RXRX | Recursion Pharmaceuticals | 204,752 |
ARKG | RPTX | Repare Therapeutics | 18,190 |
ARKG | QSI | Quantum-Si | 359,389 |
ARKG | MASS | 908 Devices | 47,945 |
ARKK | FATE | Fate Therapeutics | 535,305 |
ARKK | COIN | Coinbase Global | 20,165 |
ARKK | TSLA | Tesla | 110,731 |
ARKQ | PATH | UiPath | 135,228 |
ARKW | VUZI | Vuzix | 521,151 |
ARKW | FTCH | Farfetch | 599,955 |
ARKX | AVAV | Aerovironment | 23,098 |
ARKX | PATH | UiPath | 25,645 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality. (sponsor)
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.